Treatment of Crohn's disease and familial Mediterranean fever by leukopheresis: single shot for two targets.

Coexistence of Crohn's disease (CD) and familial Mediterranean fever (FMF) is a rare condition and knowledge about this clinical situation is limited with a few case reports in the literature. The treatment of both diseases depends on their individual therapies. However, it is very hard to deal with this coexistence when CD is refractory to standard therapies. Ongoing activity of CD triggers the clinical attacks of FMF and the symptoms like abdominal pain interfere with both disease presentations which can cause problems about diagnostic and therapeutic approach. The main therapeutic agent for FMF is colchicine and diarrhea is the most common side effect of this drug. This side effect also causes problems about management of these diseases when both of them are clinically active. Here we report probably the first case in the literature with coexisting CD and FMF who was successfully treated by leukopheresis since he was refractory to conventional therapies for CD.

[1]  K. Demır,et al.  Association of the MEFV Gene Variations With Inflammatory Bowel Disease in Turkey , 2013, Journal of clinical gastroenterology.

[2]  T. Joh,et al.  Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease , 2012, Case Reports in Gastroenterology.

[3]  Ryuichi Yamamoto,et al.  Treatment of refractory Crohn's disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases. , 2011, Internal medicine.

[4]  P. Vernia,et al.  Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  Y. Takei,et al.  Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease , 2010, Journal of clinical apheresis.

[6]  T. Matsui,et al.  An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment , 2009, The American Journal of Gastroenterology.

[7]  I. Bjarnason,et al.  Leukocytapheresis for the treatment of IBD , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[8]  B. Sands,et al.  Selective leukocyte apheresis for the treatment of inflammatory bowel disease. , 2007, Journal of clinical gastroenterology.

[9]  J. Crusius,et al.  The Familial Mediterranean Fever (MEVF) Gene as a Modifier of Crohn's Disease , 2005, The American Journal of Gastroenterology.

[10]  T. Matsui,et al.  Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study , 2004, Journal of Gastroenterology.

[11]  I. Bjarnason,et al.  Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.